Last updated 9 days ago
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
450 patients around the world
Available in Argentina
Amgen
41Research sites
450Patients around the world
This study is for people with
Colorectal cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.Central confirmation of KRAS p.G12C mutation.Measurable metastatic disease per RECIST v1.1 criteria.Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.Adequate organ function.
- Active, untreated brain metastases.Leptomeningeal disease.Previous treatment with a KRAS p.G12C inhibitor.History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan.
Sites
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
Sociedad de Beneficencia Hospital Italiano - Córdoba
Recruiting
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Centro Gutman
Recruiting
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Hospital Británico de Buenos Aires - CABA
Recruiting
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Exelsus - Oncología Clínica - Tucumán
Recruiting
Fundación Favaloro para la Docencia e Investigación Médica - CABA, Buenos Aires
Recruiting
Sanatorio Allende (Nueva Córdoba)
Recruiting
StudyCodeBreaK 301
SponsorAmgen
Study typeInterventional
Conditions
Colorectal cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06252649
